IDH3A and astrocytoma (excluding glioblastoma): However, the exploratory efficacy results of this trial are difficult to interpret, because there was no standard of care control arm, sample size per treatment arm was small and survival was not reported by treatment arm or excluding patients with isocitrate dehydrogenase-mutant astrocytomas.